Weiyan Cheng

Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Chemical methodologies for Direct-to-Biology library synthesis.

Chemical methodologies for Direct-to-Biology library synthesis.

Journal: European journal of medicinal chemistry

Published: April 28, 2026

Identification of Tumor Hypoxia-Activated Degradation-Targeting Chimeras.

Identification of Tumor Hypoxia-Activated Degradation-Targeting Chimeras.

Journal: Journal of medicinal chemistry

Published: February 21, 2026

Catalyst-Free, Divergent Cysteine Modification via Indole Isocyanide Photochemistry.

Catalyst-Free, Divergent Cysteine Modification via Indole Isocyanide Photochemistry.

Journal: Angewandte Chemie (International ed. in English)

Published: November 06, 2025

Design, synthesis, and biological evaluation of 2, 6-di-substituted indole derivatives as METTL3 inhibitors.

Design, synthesis, and biological evaluation of 2, 6-di-substituted indole derivatives as METTL3 inhibitors.

Journal: European journal of medicinal chemistry

Published: May 12, 2025

Identification of novel 2, 6-Di-substituted Imidazo[1,2-a]pyridine derivatives as potent METTL3 inhibitors.

Identification of novel 2, 6-Di-substituted Imidazo[1,2-a]pyridine derivatives as potent METTL3 inhibitors.

Journal: Bioorganic chemistry

Published: May 12, 2025

Small molecules as modulators of the proteostasis machinery: Implication in cardiovascular diseases.

Small molecules as modulators of the proteostasis machinery: Implication in cardiovascular diseases.

Journal: European journal of medicinal chemistry

Published: October 05, 2023

Discovery of novel hypoxia-activated, nitroimidazole constructed multi-target kinase inhibitors on the basis of AZD9291 for the treatment of human lung cancer.

Discovery of novel hypoxia-activated, nitroimidazole constructed multi-target kinase inhibitors on the basis of AZD9291 for the treatment of human lung cancer.

Journal: Bioorganic & medicinal chemistry

Published: March 31, 2023

Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.

Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.

Journal: Bioorganic & medicinal chemistry

Published: January 18, 2023

Chemoproteomics reveals arctigenin as a phagophore-closure blocker via targeting ESCRT-I subunit VPS28.

Chemoproteomics reveals arctigenin as a phagophore-closure blocker via targeting ESCRT-I subunit VPS28.

Journal: Bioorganic chemistry

Published: December 26, 2022

Design, synthesis and biological evaluation of novel tumor hypoxia-activated EGFR tyrosine kinase inhibitors.

Design, synthesis and biological evaluation of novel tumor hypoxia-activated EGFR tyrosine kinase inhibitors.

Journal: Bioorganic chemistry

Published: July 25, 2022

Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.

Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.

Journal: Drug design, development and therapy

Published: December 01, 2021

Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia.

Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia.

Journal: Chemical communications (Cambridge, England)

Published: November 17, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026